Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal
Clinical trial NCT07155122 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07155122
- Sponsor
- Fujian Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-01
- Primary completion
- 2027-09-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.